Wells Fargo Maintains Overweight on Zentalis Pharma, Lowers Price Target to $50
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Derek Archila has maintained an Overweight rating on Zentalis Pharma (NASDAQ:ZNTL) but lowered the price target from $51 to $50.
August 10, 2023 | 2:05 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Zentalis Pharma's price target has been lowered by Wells Fargo from $51 to $50, while maintaining an Overweight rating.
The news is directly about Zentalis Pharma and its price target. While the price target has been lowered, the Overweight rating suggests that the stock is still expected to outperform. This could have a neutral impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100